GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » EV-to-Revenue

Hansa Biopharma AB (OSTO:HNSA) EV-to-Revenue : 18.05 (As of May. 25, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Hansa Biopharma AB's enterprise value is kr2,994.7 Mil. Hansa Biopharma AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was kr165.9 Mil. Therefore, Hansa Biopharma AB's EV-to-Revenue for today is 18.05.

The historical rank and industry rank for Hansa Biopharma AB's EV-to-Revenue or its related term are showing as below:

OSTO:HNSA' s EV-to-Revenue Range Over the Past 10 Years
Min: 9.4   Med: 438.82   Max: 4104.08
Current: 18.05

During the past 13 years, the highest EV-to-Revenue of Hansa Biopharma AB was 4104.08. The lowest was 9.40. And the median was 438.82.

OSTO:HNSA's EV-to-Revenue is ranked worse than
65.8% of 1038 companies
in the Biotechnology industry
Industry Median: 8.22 vs OSTO:HNSA: 18.05

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-25), Hansa Biopharma AB's stock price is kr41.00. Hansa Biopharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr3.15. Therefore, Hansa Biopharma AB's PS Ratio for today is 13.01.


Hansa Biopharma AB EV-to-Revenue Historical Data

The historical data trend for Hansa Biopharma AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB EV-to-Revenue Chart

Hansa Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 821.81 1,528.20 91.38 12.14 11.30

Hansa Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.99 12.87 15.95 11.30 11.69

Competitive Comparison of Hansa Biopharma AB's EV-to-Revenue

For the Biotechnology subindustry, Hansa Biopharma AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansa Biopharma AB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's EV-to-Revenue falls into.



Hansa Biopharma AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Hansa Biopharma AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=2994.665/165.881
=18.05

Hansa Biopharma AB's current Enterprise Value is kr2,994.7 Mil.
Hansa Biopharma AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr165.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hansa Biopharma AB  (OSTO:HNSA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Hansa Biopharma AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=41.00/3.151
=13.01

Hansa Biopharma AB's share price for today is kr41.00.
Hansa Biopharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr3.15.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hansa Biopharma AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansa Biopharma AB (OSTO:HNSA) Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB (OSTO:HNSA) Headlines

No Headlines